New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 2, 2014
07:39 EDTCYTKCytokinetics announces further results from BENEFIT-ALS
Cytokinetics announced that additional results from BENEFIT-ALS were presented yesterday during the Joint Congress of European Neurology at the International Congress Center. In BENEFIT-ALS, patients with amyotrophic lateral sclerosis were randomized 1:1 to double-blind treatment with tirasemtiv or placebo for 12 weeks. The primary outcome measure, the ALS Functional Rating Scale in its revised form, and secondary outcomes measures of respiratory performance and other measures of skeletal muscle function and fatigability were assessed after 4, 8, and 12 weeks of double-blind treatment, and again at 1 and 4 weeks after the last dose of double-blind treatment. The results from double-blind treatment during BENEFIT-ALS were presented at the Annual Meeting of the American Academy of Neurology.
News For CYTK From The Last 14 Days
Check below for free stories on CYTK the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 30, 2014
16:10 EDTCYTKCytokinetics reports Q2 EPS (23c), consensus (32c)
Reports Q2 revenue $7.8M, consensus $7.01M.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use